News News Details

2018年,倚锋创投将在全新高度迎接更大机遇与挑战

Date: 2018-02-02
Views: 39

 2018年2月10日,在迎接农历新年的喜庆祥和氛围中,倚锋创始人朱晋桥、合伙人任正黎、合伙人胡乃波以及全体员工共同参与了倚锋创投举行2017年度工作总结会暨优秀员工表彰活动。


2018年,倚锋创投将在全新高度迎接更大机遇与挑战


会议开始,各部门对2017年度工作做出回顾和盘点,汇报工作中取得的成绩以及总结不足和将继续加强的方面。从总结中可以看出,倚锋的2017年是充满收获的一年,公司较好地完成年度目标,同时还保持着持续的增长趋势。在资金募集方面,市场部与投资部顺利完成倚锋睿意基金的追慕、倚锋睿博基金的募集、倚锋八期基金(美元)和倚锋九期基金(人民币)的大部分募集。公司资金募集较上年同期增长49.4%,全年营收较上年同期增长44.23%,全年税前利润较上年同期增长近三倍。此外,在投资部国内国外的科学家们的联动配合下,公司还新增储备数十个优秀项目,为新一年的工作开展奠定了坚实的基础。


2018年,倚锋创投将在全新高度迎接更大机遇与挑战


接下来,倚锋创始人朱晋桥先生做了发言—“奋斗实现人生价值,奉献改变生命格局”,鼓励全体员工在新的一年中共同努力、迎接挑战,奋斗拼搏,将倚锋创投带到一个新的高度。


2018年,倚锋创投将在全新高度迎接更大机遇与挑战2018年,倚锋创投将在全新高度迎接更大机遇与挑战


热情洋溢的讲话结束后是优秀员工表彰会。公司设置了“最佳团队奖”、“锲而不舍奖”、“伯乐奖”、“优秀员工奖”等奖项,由朱晋桥先生、任正黎女士和胡乃波先生亲自为获奖员工,包括:公司的财务部、首席科学官肖卫民博士、投资部总监马良肖博士、市场部总监雷宇等颁奖。


2018年,倚锋创投将在全新高度迎接更大机遇与挑战2018年,倚锋创投将在全新高度迎接更大机遇与挑战
2018年,倚锋创投将在全新高度迎接更大机遇与挑战2018年,倚锋创投将在全新高度迎接更大机遇与挑战


此外,公司还任命杨敏女士为倚锋副总裁、何娇兰为财务经理,并为她们颁发任命书。


2018年,倚锋创投将在全新高度迎接更大机遇与挑战2018年,倚锋创投将在全新高度迎接更大机遇与挑战


最后,倚锋合伙人任正黎女士为整个会议做了总结性发言。鼓励全体倚锋人在发挥华为精神的同时,结合并发展自身的优势,希望大家2018年继续奋斗,再创佳绩!


2018年,倚锋创投将在全新高度迎接更大机遇与挑战2018年,倚锋创投将在全新高度迎接更大机遇与挑战


倚锋的2017年已画上圆满的句号。新的一年充满机遇与挑战,相信每个倚锋人已经做好准备,一起努力,共同奋斗,迎接崭新的2018!


Related News / Recommended news More
2026 - 03 - 24
In March, Suzhou is gradually embracing the vitality of spring, much like China's biomedical industry, which is gathering momentum amidst transformation. On March 13, during the 11th BioChina Summit (BIOCHINA 2026), Mr. Zhu Pai, CEO of Efung Capital, was invited to attend the core session—the Global Investment Forum—where he engaged in in-depth discussions with industry peers on the theme &quo...
2026 - 03 - 25
Frontier Biotechnologies Inc. (“Frontier Biotechnologies” or the “Company”) recently entered into an exclusive licensing agreement with global biopharmaceutical company GlaxoSmithKline (“GSK”). Under the agreement, GSK will obtain exclusive worldwide rights for the development, manufacturing, and commercialization of two siRNA pipeline assets. One candidate drug has reached the Investigational New...
2026 - 03 - 06
Oryzogen's Orumin® Phase IV Clinical Trial Completes First Dosing | Portfolio NewsOn March 5, 2026, the Phase IV clinical study of Oryzogen's recombinant human albumin (rice-derived) Orumin®, evaluating its "safety and efficacy in patients with hypoalbuminemia and/or hypovolemia requiring emergency treatment," achieved its first patient enrollment and completed the init...
2026 - 03 - 05
The year 2026 marks the beginning of the 15th Five-Year Plan period. Recently, the 11th batch of the “Outstanding Domestic Medical Equipment Product Catalogue” was officially released. Viestar’s independently developed BIOPSEE® Confocal Laser Endomicroscope and BIOPSEE® Ultra-Thin Probe-based Confocal Laser Endomicroscope were prominently selected. This recognition makes JWS Medical the ...
Address: 505 China Resources Building, 2666 Keyuan South Road, Nanshan District, Shenzhen
TEL:0755-8831-6141
E-mail:info@efungcapital.com
Copyright ©2018 - 2021 Shenzhen Efung Investment Management Co. Ltd.
Rhino Cloud provides enterprise cloud services
犀牛云提供云计算服务